Craniospinal Irradiation (CSI) in Acute Lymphoblastic Leukemia: Comparison between Conformal Radiotherapy, Intensity-Modulated Radiotherapy, and Helical Tomotherapy (HT)

Jacob J1, Vernant JP1, Chira C1, Mazal A1, Zefkili S1, Dauphinot C1, Campana F1, Alapetite C1, Fourquet A1 and Kirova YM1*

1Department of Radiation Oncology, Institut Curie, Paris, France
2Department of Hematology, Pitie Salpetriere Hospital, Paris, France

Abstract

**Purpose:** According to preliminary clinical experience, craniospinal irradiation (CSI) may be considered as a treatment option in patients with recurrent leukemia involving the central nervous system (CNS). Field matching poses challenges as it leads to a risk of underdosage or overdosage in the junctional area. We investigated the feasibility of CSI using helical tomotherapy (HT).

**Patients and methods:** Four patients presenting with CNS recurrences of leukemia were referred to our department for salvage radiation therapy. Treatment planning was conducted by the Eclipse™ system for 3D-CRT and IMRT, and with the Tomotherapy® software for HT. Acute adverse events were monitored weekly using the Common Terminology Criteria for Adverse Events v 4.0.

**Results:** Using HT, highly conformal irradiation could be delivered to CNS. Average doses to the encephalon were 25.1 Gy, 15.5 Gy, and 23.3 Gy using 3D-CRT, IMRT, and HT respectively. Spinal cord received an average dose of 18.9 Gy with 3D-CRT, 15.7 Gy with IMRT and 23.4 Gy with HT. Areas of overdosage to the brain or the spinal cord were also significantly decreased with HT. With HT, average doses to critical organs were also significantly decreased. No acute toxicity was reported with HT, whereas the patients treated by 3D-CRT and IMRT presented with grade II vomiting and asthenia.

**Conclusion:** HT may optimize CSI in the treatment of CNS hematological recurrences by homogeneously covering target volumes and improve clinical acute tolerance by more effectively sparing critical organs for preserving the quality of life. Further prospective assessments are warranted.

**KeyWords:** Craniospinal irradiation; Acute lymphoblastic leukemia; Central nervous system; Helical Tomotherapy

**Introduction**

Acute lymphoblastic leukemia (ALL) is a malignant hemopathy arising from clonal expansion of lymphoid blasts [1]. This heterogeneous disease is one of the most frequent malignancies in children in the United States [2]. In France, incidence rate in children younger than 15 years old was 34.3 cases per million per year [3], but data concerning adults is scarce. The register of Basse-Normandie region reports an incidence of 2.7% in the 1997–2004 period [4]. Several prognosis factors have been described [5,6] ALL rarely involve the central nervous system (CNS) at diagnosis [7], but the risk of relapse there without prophylaxis is particularly high [8,9]. Local neurologic recurrence alters prognosis [10,11] and constitutes a therapeutic challenge.

Radiotherapy has been one of the therapeutic modalities for CNS prophylaxis and relapses in ALL for decades, although its potential for long-term toxicity prevents its choice as first line treatment at some centres, in favor of systemic and/or intrathecal treatments [12]. However, several techniques have emerged with efficient dose delivery and assurance of local control, while sparing healthy organs: first 3D-conformal radiotherapy (3D-CRT), then intensity-modulated radiotherapy (IMRT), and finally helical tomotherapy (HT) [13-15].

Here, we report our observations of four patients treated with craniospinal irradiation (CSI) via these three modalities at our institution for CNS-extended ALL. We also describe dosimetric studies for each method and clinical implications in terms of local control and acute tolerance.

**Patients and Methods**

**Case No.1**

A thirty-two-year-old woman was diagnosed with ALL in December 2007 characterized by the presence of the CALM/AF10 transcript [10,11] (p13,q14) and normal karyotype. She was first treated with chemotherapy (Table 1) followed by an autologous bone marrow transplantation, leading to a complete remission. Due to her altered general status, the patient was administered fewer intrathecal injections for CNS prophylaxis (methotrexate, cytarabine, depomedrol) (Table 2) and no total body irradiation (TBI) during the conditioning of the autograft.

In August 2009, headaches revealed a meningeal relapse observed in the cerebrospinal fluid (CSF). Clinical examination and a complete transcript [10,11] (p13,q14) and normal karyotype. She was first treated with chemotherapy (Table 1) followed by an autologous bone marrow transplantation, leading to a complete remission. Due to her altered general status, the patient was administered fewer intrathecal injections for CNS prophylaxis (methotrexate, cytarabine, depomedrol) (Table 2) and no total body irradiation (TBI) during the conditioning of the autograft.

In August 2009, headaches revealed a meningeal relapse observed in the cerebrospinal fluid (CSF). Clinical examination and a complete evaluation of the bone marrow revealed normal results. Thus the patient was treated with intrathecal chemotherapy and corticosteroids. Due to
the persistence of the symptoms, a magnetic resonance imaging (MRI) was performed and showed a lesion of the cerebellum compatible with a chloroma. A tonsillar and transtentorial involvement was also observed.

A second round of chemotherapy including methotrexate and cytarabine was delivered. However, the first cycle was complicated by mental adverse events and severe respiratory failure, requiring an orotracheal intubation and ventilator derivation.

After clinical improvement, the patient received an intrathecal injection of liposomal cytarabine and corticosteroids, then a second cycle of systemic methotrexate and cytarabine. This treatment was successful from a biological and radiological point-of-view, manifested by CSF depletion of blastic cells, marked shrinkage of the cerebellar lesion, and regression of the mass effect on MRI.

In order to reinforce this favorable tableau, CSI via 3D-CRT was deemed appropriate. The delivered dose was 18 Gy (1.8 Gy per fraction) to the CNS with a boost of 40 Gy to the cerebral posterior fossa, with 6MV and 20 MV photons in the prone position.

### Case No.2

A 14-year-old boy was diagnosed with Philadelphia-negative ALL with two myeloid markers (CD 13, CD 33) and hyperleukocytosis in March 2001. A chemotherapy induction (daunorubicin, vincristine, L-asparaginase, methylprednisolone) was performed and followed by a consolidation with cytarabine and cyclophosphamide. CNS prophylaxis was administered through intrathecal injections of methotrexate, cytarabine, and depomedrol.

Molecular residual disease was intact in August 2001 and was treated by intensive chemotherapy (Table 1) and prophylactic intrathecal injections (Table 2). Due to the absence of a geno-identic donor of bone marrow, a graft could not be performed.

In October 2009, at the age of 23, the patient presented with headaches, revealing a CNS relapse. Blastic cells were found in the CSF, whereas Computed Tomography (CT) and MRI remained normal. Therefore, systemic treatment with methotrexate, cytarabine, and intrathecal injections (methotrexate, cytarabine, depomedrol) were administered.

---

### Table 1: Patients’ clinical and systemic treatment features.

<table>
<thead>
<tr>
<th>Patient</th>
<th>CNS prophylactic treatment</th>
<th>Time to CNS relapse (months)</th>
<th>CNS curative treatment</th>
<th>Graft</th>
<th>Radiation therapy modality</th>
<th>Delivered dose to CNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IT methotrexate, cytarabine, depomedrol</td>
<td>20</td>
<td>IV methotrexate, cytarabine IT liposomal cytarabine and corticosteroids CSI</td>
<td>No</td>
<td>3D-CRT 6 MV photons</td>
<td>18 Gy (10 fractions) + boost until 40 Gy to cerebral posterior fossa</td>
</tr>
<tr>
<td>2</td>
<td>IT methotrexate, cytarabine, depomedrol</td>
<td>103</td>
<td>IV methotrexate, cytarabine IT methotrexate, cytarabine, depomedrol CSI</td>
<td>Yes</td>
<td>IMRT 6 and 20 MV photons</td>
<td>15 Gy (10 fractions)</td>
</tr>
<tr>
<td>3</td>
<td>IT methotrexate, cytarabine, corticosteroids</td>
<td>56</td>
<td>IV cyclophosphamide, methotrexate, doxorubicin, vincristine, cytarabine and dexamethasone IT liposomal cytarabine CSI</td>
<td>No</td>
<td>HT 6 MV photons</td>
<td>23.4 Gy (13 fractions)</td>
</tr>
<tr>
<td>4</td>
<td>No</td>
<td>0</td>
<td>IV hydroxyurea, idarubicin, cytarabine, Oral imatinib, IT cytarabine (conventional then liposomal), methotrexate and corticosteroids CSI</td>
<td>No</td>
<td>HT 6 MV photons</td>
<td>23.4 Gy (13 fractions)</td>
</tr>
</tbody>
</table>


Table 2: Central nervous system treatment features.

---

**J Nucl Med Radiat Ther** Cancer Radiation Therapy ISSN:2155–9619 JNMRT an open access journal

The patient received CSI (15 Gy, 1.5 Gy per fraction) by IMRT in prone position with 6 MV photons beams to the the whole brain and 20 MV photons on the superior and inferior central neuraxis.

Case No.3

A 45-year-old man was treated by HT for neurological and testicular relapse of Philadelphia-positive ALL.

The disease was diagnosed in December 2005 and was treated first by induction chemotherapy comprised of vincristine, dexamethasone, and imatinib. CNS prophylaxis was also performed through intrathecal injections of methotrexate and cytarabine. Once complete remission was attained, consolidation chemotherapy by systemic methotrexate and cytarabine was delivered. In April 2006, an allograft was carried out after conditioning by TBI (12 Gy in six fractions) and cyclophosphamide.

The patient presented with two relapses. The first one occurred in December 2007 in peripheral blood and bone marrow. Molecular residual disease was diagnosed. Chemotherapy was delivered according to the Capizzi protocol (Table 1) followed by a maintenance regimen including dasatinib, nilotinib, and donor lymphocyte infusion. Prophylactic intrathecal injections of methotrexate, cytarabine, and corticosteroids were delivered.

The second recurrence developed in the right testicle and CNS in August 2010. Intensive chemotherapy (cyclophosphamide, methotrexate, doxorubicin, vincristine, cytarabine, and dexamethasone) and intrathecal injections (liposomal cytarabine) were administered (Table 2). Due to this second relapse, we decided to irradiate the two involved sites.

The irradiation was performed through HT with 6 MV photons, 23.4 Gy (1.8 Gy per fraction) to the CNS and 24 Gy to the testicles because this was the region of the first recurrence. The first part of the irradiation included both testicles and took place in December 2010. The treatment was followed by a complication in the form of a grade I erythema treated with topical corticosteroids.

The irradiation of the CNS was performed in dorsal decubitus and started in January 2011. A prophylactic treatment against potential adverse effects was administered (prevention of headaches, nausea by corticosteroids).

Case No.4

A 58-year-old woman presented in March 2010 with lumbar pains whose intensity progressively increased. The results of initial clinical and radiological examinations appeared normal. Two weeks later, a lack of motility in the lower right leg occurred. No abnormality regarding sensitivity and sphincters was observed. The first hematologic evaluation showed hyperleukocytosis (200,000 white cells/mm³, 12,000 basophiles, and 8,000 eosinophiles), anemia (hemoglobin: 9.0 g/dl), thrombocytosis (560,000 platelets/mm³), and 11% of blastic cells. The myelogram showed hyperplasia of granulopoiesis with basophilia, 9% myeloblasts, and relative hypoplasia of erythropoiesis. Karyotype in peripheral blood showed the existence of the Philadelphia chromosome. Moreover, the CSF contained 88% blastic cells. MRI showed infiltration extending from the third lumbar to the first two sacral vertebrae. And so, the diagnosis of myeloid chronic Philadelphia-positive leukemia with an ALL aspect and extension to the CNS was established. After a cytoreduction by hydroxyurea, chemotherapy induction with idarubicin and cytarabine, accompanied with oral imatinib, was initiated in April 2010 (Table 1).

The CNS was locally treated with intrathecal methotrexate, cytarabine (conventional first, then liposomal), and corticosteroids (Table 2). Consolidation chemotherapy was delivered (idarubicin, cytarabine) from August to October with a cytogenetic complete response to the treatment. Imatinib and intrathecal injections of liposomal cytarabine were continued.

A bone marrow transplant could not be performed due to the absence of a compatible donor either among family members or in the international databank, a fetoplacental allograft was counterindicated due to the prevalence of anti-human-leukocyte antibodies in the blood. A collection of peripheral stem cells also failed.

Hence, after deliberations by a multidisciplinary team considering this controlled disease, it was decided to perform CSI. The treatment was conducted in the supine position by HT, using 6-MV photons and targeting the entire CNS (23.4 Gy, 1.8 Gy per fraction).

Physics

Dosimetry was performed using the Eclipse Treatment Planning System (Varian Medical Systems, Palo Alto, CA) for 3D-CRT and IMRT, and Tomotherapy® (Accuray Incorporated, Sunnyvale, CA) software for HT. These systems were employed in the treatment planning performed for every patient. Data reported on HT were calculated by determining the average of the doses prescribed for each of the two patients treated.

Clinical assessment

For every patient, acute adverse events were recorded weekly, using the Common Terminology Criteria for Adverse Events v 4.0.

Results

Target volume coverage

The average doses prescribed to the 100% of the planning target volumes were 25.1 Gy to the encephalon (139.4% of the prescription dose), 40.2 Gy to the posterior cerebral fossa (100.5%), 18.9 Gy to the spinal cord (105.9%) with 3D-CRT. The patient treated by IMRT received an average dose of 15.5 Gy to the encephalon (103.3% of the prescription dose), and 15.7 Gy to the spinal cord (104.6%). In the case of the two patients treated through HT, both encephalon and spinal cord were targeted with an average dose of 23.3 Gy (99.5% of the prescription dose) (Figure 1 and 2). These results are reported in Table 3.

Average doses to organs at risk

Average doses received according to the plans by the esophagus were 16.0 Gy (3D-CRT), 13.4 Gy (IMRT), and 10.5 Gy (HT), by both lungs 3.3 Gy (3D-CRT), 2.2 Gy (IMRT), and 4.1 Gy (HT), and by the heart 11.4 Gy (3D-CRT), 8.0 Gy (IMRT), and 4.9 Gy (HT).

According to the treatment plans, the right lens received an average of 5.5 Gy by 3D-CRT, 1.2 Gy by IMRT, and 2.3 Gy by HT. The left lens had 6.5 Gy with 3D-CRT, 1.0 Gy with IMRT, and 2.3 Gy with HT. The larynx had 6.3 Gy on 3D-CRT, 1.0 Gy with IMRT, and 10.2 Gy on HT. The thyroid gland received 14.2 Gy on 3D-CRT, 12.1 Gy on IMRT, and 6.7 Gy on HT.

All these results are shown in Table 4.

Acute adverse events

The patient treated by 3D-CRT presented during CSI with grade...
Six months after the end of the irradiation, the clinical symptoms completely disappeared, allowing a progressive decrease in the corticotherapy doses. However, the patient developed a loss of sensitivity in the posterior right thigh six months post treatment. The neurological symptoms disappeared three months later. Radiological follow-up by MRI showed a complete regression of the cerebellar lesion and no relapse in the brain or in the medullar axis either. The blood cell count remained normal. Performance status improved so that the patient was able to engage in professional activity.

The young patient whose treatment was performed by IMRT experienced grade II vomiting controlled by symptomatic medication. His performance status was preserved and he developed no other symptoms. No biological abnormality was detectable on the blood cell count. Then, in April 2010, the patient received a pheno-identical allograft following conditioning by TBI (12 Gy in six fractions) and cyclophosphamide.

The first patient treated by HT did not suffer any acute clinical toxicity. He remained asymptomatic during the whole treatment. The biological examination showed a grade 0 anemia (hemoglobin: 10.8 g/dL) and a grade 0 lymphopenia (lymphocytes: 1100/mm³), whereas platelets count remained normal.

HT had to be stopped during the second patient’s treatment after a dose of 9 Gy was delivered to the CSA. She was admitted to the Hematology department for disease progression.

II vomiting and asthenia, and grade I epithelitis. She also complained about postural headaches and cervical paresthesias. Biological examination showed grade II pancytopenia, requiring hematopoietic growth factors and platelet transfusions.
Discussion

CSI is usually performed on tumors involving the CNS such as medulloblastomas [16-17], germinomas [18], and ependymomas [19]. As far as hematologic tumors are concerned, lymphomas can constitute an indication for this type of radiation therapy [20]. Intensification therapy, including CSI, has been assessed by Lazarus et al. in patients with acute CNS lymphoblastic leukemia [21]. Despite the treatment, this condition presented a higher risk of CNS relapse and a shorter overall survival. A single cranial irradiation was performed to prevent or treat local failure of this malignant hemopathy [22].

Different techniques have been described to perform radiation therapy on the craniopspinal axis. Prone position allows efficient coverage of the spinal cord, but risk organs (thyroid gland, mandible, pharynx, and larynx) may receive higher doses [23]. Supine position has been assessed in children [24], delivering doses to the spinal cord similar to the prescription dose, while saving setup time.

CSI may lead to various adverse effects: acute hematologic [25], otologic [26], digestive [27], late endocrine, central, and peripheral neurological [28,29] toxicities [30], affected fertility [31,32] and increased risk of second malignancy [33-35].

Due to these potential impairments, different techniques have been studied in order to maintain local control and improve quality of life, such as proton therapy [36], IMRT [37], and hyperfractionation [38]. HT, when indicated for a case of CSI, presents dosimetric advantages, such as no field junction and no discontinuous gantry movements [39]. Despite the relatively long time dedicated to setup and treatment, image guidance with CT assures a precise and safe irradiation [40].

From a physical point-of-view, HT is superior to conformal radiotherapy and IMRT in terms of dose homogeneity index and conformity index. Doses to risk organs are also reduced [41-44].

Compared to conventional radiotherapy, in pediatric patients, this method delivers a lower dose level to the growing vertebrae [45]. Acute pulmonary toxicity is improved [46].

However, the main difficulty encountered with HT is the fact that a substantial volume of healthy tissues receive low doses (Figure 3) [47,48]. After calculation of organ-equivalent doses, risk of secondary cancers in relationship to the irradiation of organs at risk seems to be higher with HT than with proton therapy [49]. Variations in spinal cord setup can generate gaps in terms of delivered doses to the CNS between initial dosimetric evaluation and effective treatment [50]. Moreover, in some cases, optic nerve could be partially underdosed, so that the risk of local recurrences would be increased in tumors with tropism for the CNS [51].

Conclusion

According to our study, compared to conformal radiotherapy, HT covers efficiently the planning target volume and contributes to local control while delivering lower doses to risk organs. Despite a longer time dedicated to set-up and treatment, acute adverse events are acceptable. Hence, HT constitutes a reliable modality of CSI. Main drawbacks of this technique are low-dose distribution to healthy tissues and variations in setup despite daily monitoring by CT. A longer follow-up of these patients, especially young ones, is warranted to assess chronic toxicity related to the treatment, particularly secondary malignancies.

Acknowledgements

To Acuray France for the help in this paper’s revision

References


Submit your next manuscript and get advantages of OMICS Group submissions

**Unique features:**
- User-friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

**Special features:**
- 200 Open Access journals
- 15,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing in PubMed (portail), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/biochem